These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003 [TBL] [Abstract][Full Text] [Related]
25. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases. Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492 [TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis. Gümus M; Ozgur A; Tutar L; Disli A; Koca I; Tutar Y Curr Pharm Biotechnol; 2016; 17(14):1231-1245. PubMed ID: 27804852 [TBL] [Abstract][Full Text] [Related]
27. Designing, structural elucidation, comparison of DNA binding, cleavage, radical scavenging activity and anticancer activity of copper(I) complex with 5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one Schiff base ligand. Sathiyaraj S; Sampath K; Butcher RJ; Pallepogu R; Jayabalakrishnan C Eur J Med Chem; 2013 Jun; 64():81-9. PubMed ID: 23644191 [TBL] [Abstract][Full Text] [Related]
28. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC). Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447 [TBL] [Abstract][Full Text] [Related]
29. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening. Park H; Kim YJ; Hahn JS Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098 [TBL] [Abstract][Full Text] [Related]
30. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation. Abbasi M; Sadeghi-Aliabadi H; Amanlou M Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484 [TBL] [Abstract][Full Text] [Related]
31. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Sakkiah S; Thangapandian S; John S; Lee KW Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051 [TBL] [Abstract][Full Text] [Related]
32. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277 [TBL] [Abstract][Full Text] [Related]
33. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening. Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488 [TBL] [Abstract][Full Text] [Related]
34. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity. Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297 [TBL] [Abstract][Full Text] [Related]